Argo Biopharma Announces Phase 2 Advancement and Milestone Payment for siRNA Molecule BW-00163

Argo Biopharma to Present Promising Phase 1/2a Results of siRNA Therapeutic BW-20507 for Chronic Hepatitis B at EASL Congress 2025 (Late-Breaker)

Argo Biopharma to Present at the J.P. Morgan 43rd Annual Healthcare Conference

Argo Biopharma Announces Completion of First Participant Dosing in China Phase I Clinical Study of BW-03, a Novel RNAi Therapeutics for the Treatment of CHB

First Patient Dosed in Phase 2 Clinical Trial of Argo Biopharma BW-01, a Novel siRNA Drug for the Treatment of Severe Hypertriglyceridemia

Argo Biopharma has completed phase 1 clinical trials for BW-01, a siRNA candidate for cardiovascular diseases, in China and Australia.